The conclusions of these studies all support our current research that Fos is more likely to be involved in biological regulation and interconnected with IRI-AKI and could act as a biomarker, which might be used to assess the severity of IRI and verify the effectiveness of treatments. This evidence concerns the gene FOS and acute kidney injury.